(Q36865966)

16 August 2017

title

Mortality associated with selegiline in Parkinson's disease. What do the available data mean? (English)

1 reference

16 August 2017

1 reference

1

Y Mizuno

1 reference

16 August 2017

2

T Kondo

1 reference

16 August 2017

publication date

1 May 1997

1 reference

16 August 2017

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

289-294

1 reference

Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by dopa and iron

16 August 2017

cites work

1 reference

12 December 2020

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

1 reference

12 December 2020

Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease

1 reference

12 December 2020

Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial

1 reference

12 December 2020

Neurotoxicity of levodopa on catecholamine-rich neurons

1 reference

12 December 2020

L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease

1 reference

12 December 2020

Toxic and protective effects of L-dopa on mesencephalic cell cultures

1 reference

12 December 2020

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death

1 reference

12 December 2020

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation

1 reference

12 December 2020

Multi-center study of Parkinson mortality with early versus later dopa treatment

1 reference

12 December 2020

Parkinsonism treated with levodopa: progression and mortality.

1 reference

12 December 2020

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom

1 reference

12 December 2020

Deprenyl in Parkinson's disease

1 reference

12 December 2020

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1 reference

12 December 2020

Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease

1 reference

12 December 2020

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary

1 reference

12 December 2020

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

1 reference

12 December 2020

The effect of L-Deprenyl on on-off phenomena in Parkinson's disease

1 reference

12 December 2020

Atrial fibrillation induced by selegiline

1 reference

12 December 2020

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients

1 reference

12 December 2020

Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa

1 reference

12 December 2020

Selegiline in Parkinson's disease

1 reference

12 December 2020

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

12 December 2020

1 reference

12 December 2020

Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients

1 reference

12 December 2020

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

1 reference

12 December 2020

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

1 reference

12 December 2020

Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?

1 reference

12 December 2020

Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease

1 reference

12 December 2020

L-deprenyl treatment of on-off phenomena in Parkinson's disease

1 reference

12 December 2020

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality

1 reference

12 December 2020

L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress.

1 reference

12 December 2020

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages

1 reference

12 December 2020

Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging

1 reference

12 December 2020

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons

1 reference

12 December 2020

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease

1 reference

12 December 2020

Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons

1 reference

12 December 2020

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations

1 reference

12 December 2020

Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease

1 reference

12 December 2020

Selegiline in de novo parkinsonian patients: the Finnish study

1 reference

12 December 2020

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used

1 reference

12 December 2020

Mortality associated with early and late levodopa therapy initiation in Parkinson's disease

1 reference

12 December 2020

10.2165/00002018-199716050-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1053742954

0 references

1 reference